Table 1.
Characteristics of study samples for (epi)genetic analysis
| Parameter (mean ± SD) | CVD study participants | Population cohort | |
|---|---|---|---|
| HYPEST | CADCZ | EGCUT | |
| No of individuals | 192 | 166 | 165 |
| Men/women | 93/99 | 114/52# | 72/93* |
| Age (years) | 50.5 ± 5.2 | 50.1 ± 4.6 | 41.6 ± 22.7* |
| BMI (kg/m2) | 30.2 ± 5.4 | 27.3 ± 4.1# | 25.0 ± 4.8* |
| SBP (mmHg) | 140.1 ± 18.7 | 127.1 ± 16.2# | 123.1 ± 17.4* |
| DBP (mmHg) | 88.6 ± 11.7 | 81.5 ± 9.5# | 76.5 ± 10.6* |
| Total cholesterol (mmol/L) | 5.6 ± 1.2 | 5.3 ± 0.9# | 5.3 ± 1.1 |
| LDL (mmol/L) | 3.7 ± 1.0 | 3.1 ± 0.8# | 3.2 ± 0.9* |
| HDL (mmol/L) | 1.5 ± 0.4 | 1.3 ± 0.4# | 1.6 ± 0.4* |
| Triglycerides (mmol/L) | 1.7 ± 1.2 | 1.9 ± 1.2 | 1.4 ± 0.9* |
| HMW adiponectin (ng/mL) | 4,564.3 ± 3,602.9a | NA | NA |
| Clinically diagnosed hypertension (%) | 86.4 | 25.5# | 11.5* |
| Coronary artery disease (%) | 22.2 | 50# | 6.1* |
| Early (<58 years) myocardial infarction (%) | 14.6 | 44.6# | 0.6* |
| Antihypertensive treatment (%) | 86.4 | 25.5 # | 24.2* |
| Antilipidemic treatment (%) | 15.6 | 32.5# | 5.5* |
HMW high molecular weight, CADCZ Coronary Artery Disease in Czech, CVD cardiovascular disease, EGCUT University of Tartu Estonian Genome Center, HYPEST HYPertension in ESTonia
#HYPEST versus CADCZ, * HYPEST + CADCZ versus EGCUT, P < 0.05; the Chi-square test for categorical and the Student’s t test or Mann–Whitney test for continuous variables that had a normal or skewed distribution, respectively
aMen 3,268.3 ± 2,811.5 ng/mL; women 5,701.6 ± 3,842.8 ng/mL